Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givosiran in Acute Intermittent Porphyria
NCT02452372Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- May 2015
- Primary completion
- Sep 2017
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 1, randomised, single-blind trial in acute intermittent porphyria (AIP) comparing givosiran (ALN-AS1) with Placebo (2 arms). Primary endpoint: Safety and Tolerability (AEs, SAEs, Discontinuations) at Day 168. Started May 2015; status: completed.
02
Drugs
givosiran
03
Conditions
acute intermittent porphyria (AIP)
Beyond the preview
Go deeper on NCT02452372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452372.